Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 11/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20765756 | 0.81 | MAPK14 (0.72) | GHSRMAPK14LMNAKDM4EALDH1A1 | |
| SCHEMBL17443852 | 0.81 | GHSR (0.75) | GHSRMAPK14KDM4EALDH1A1HSD17B10 | |
| SCHEMBL16002856 | 0.80 | GHSR (0.69) | GHSRMAPK14KDM4EALDH1A1HSD17B10 | |
| SCHEMBL1355458 | 0.79 | GHSR (0.71) | GHSRMAPK14KDM4EALDH1A1HSD17B10 | |
| SCHEMBL29944074 | 0.79 | GHSR (0.71) | GHSRMAPK14KDM4EALDH1A1HSD17B10 | |
| SCHEMBL14028477 | 0.79 | GHSR (1.00) | GHSRMAPK14HPGD | |
| SCHEMBL3235960 | 0.78 | GHSR (0.67) | GHSRMAPK14KDM4EALDH1A1HSD17B10 | |
| SCHEMBL29990457 | 0.78 | GHSR (0.67) | GHSRMAPK14KDM4EALDH1A1HSD17B10 | |
| SCHEMBL143751 | 0.77 | GHSR (0.65) | GHSRMAPK14KDM4EALDH1A1HSD17B10 | |
| SCHEMBL31428636 | 0.77 | GHSR (0.65) | GHSRMAPK14KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1773880-A4 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| EP-1773880-A2 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005121175-A2 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | CD4, CD74, HAVCR2 | GHSR 3636/4885MAPK14 2202/4885LMNA 4015/4885 |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CD4, CD74, HAVCR2 | GHSR 3636/4885MAPK14 2202/4885LMNA 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.